FLUCONAZOLE INJECTION SDZ 2 MG
FLUCONAZOLE : 2 MG · DIN 02388448 · SANDOZ CANADA INCORPORATED
Health Canada status: MARKETED
What is FLUCONAZOLE INJECTION SDZ?
FLUCONAZOLE INJECTION SDZ 2 MG contains FLUCONAZOLE : 2 MG. It is listed in the Health Canada Drug Product Database under DIN 02388448, held by SANDOZ CANADA INCORPORATED, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 18-Oct-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is FLUCONAZOLE INJECTION SDZ used for?
Oropharyngeal/esophageal candidiasis; serious systemic candidal infections (UTI, peritonitis, pneumonia); cryptococcal meningitis; prophylaxis in bone marrow transplant patients.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02388448 |
|---|---|
| Brand name | FLUCONAZOLE INJECTION SDZ |
| Generic / active ingredient | FLUCONAZOLE : 2 MG |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 2 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | J02AC01 FLUCONAZOLE |
| AHFS class | 08:14.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 18-Oct-2012 |
| Original market date | 2012-10-18 00:00:00 |
How is it administered?
Adults: 100-400 mg daily depending on indication. Children: 3-12 mg/kg daily. Administer by IV infusion at max 200 mg/hour. Loading dose is twice the daily dose on day 1.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C. Protect from freezing. (Note: General standard for such solutions, though specific text was truncated, 11 STORAGE section is referenced).
How is it supplied?
100 mL single use vials, boxes of 1.
Contraindications
Hypersensitivity to fluconazole or azoles. Co-administration with CYP3A4 metabolized drugs that prolong QT interval (e.g., erythromycin, pimozide, quinidine).
Warnings and precautions
Rare cases of serious hepatic toxicity and exfoliative skin disorders (DRESS, SJS). Risk of QT prolongation and torsade de pointes. Potential for adrenal insufficiency.
What can be used instead?
Other Canadian products sharing ATC code J02AC01 FLUCONAZOLE. 29 of 71 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACT FLUCONAZOLE | 100 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02281279 |
| ACT FLUCONAZOLE | 50 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02281260 |
| AG-FLUCONAZOLE | 150 MG | CAPSULE | ANGITA PHARMA INC. | MARKETED | DIN 02555891 |
| APO-FLUCONAZOLE | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 02237371 |
| APO-FLUCONAZOLE | 50 MG | TABLET | APOTEX INC | MARKETED | DIN 02237370 |
| APO-FLUCONAZOLE-150 | 150 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02241895 |
| BIO-FLUCONAZOLE | 150 MG | CAPSULE | BIOMED PHARMA | MARKETED | DIN 02462168 |
| CANESORAL | 150 MG | CAPSULE | BAYER INC | MARKETED | DIN 02311690 |
| DIFLUCAN | 2 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 00891835 |
| DIFLUCAN | 50 MG / 5 ML | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02024152 |
Who else supplies FLUCONAZOLE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. FLUCONAZOLE appears in 503 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.